Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,812,161 papers from all fields of science
Search
Sign In
Create Free Account
SB 203207
Known as:
SB-203207
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Indenes
Sulfonamides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Toward the Synthesis of SB-203207: Construction of Four Contiguous Nitrogen-Containing Stereogenic Centers.
I. Hayakawa
,
Anna Nagayasu
,
A. Sakakura
Journal of Organic Chemistry
2019
Corpus ID: 207964140
SB-203207 is an altemicidin-type alkaloid that potently inhibits isoleucyl tRNA synthetase activity. Its main structural feature…
Expand
2006
2006
FERMENTATION, ISOLATION, AND PROPERTIES
H. Wagman
,
R. Testa
,
Joseph
,
A.
,
Márquez
2006
Corpus ID: 12895773
Antibiotic 6640 is produced by aerobic submerged fermentation of a new species of organism, Micromonospora inyoensis (NRRL 3292…
Expand
2003
2003
Synthesis and activity of analogues of the isoleucyl tRNA synthetase inhibitor SB-203207.
C. Crasto
,
A. K. Forrest
,
+8 authors
C. Easton
Bioorganic & Medicinal Chemistry
2003
Corpus ID: 45912486
2001
2001
Multi-component assembly of the bicyclic core associated with the tRNA synthetase inhibitors SB-203207 and SB-203208. Application to the synthesis of biologically active analogues.
M. Banwell
,
C. Crasto
,
+7 authors
W. Yue
Chemical Communications
2001
Corpus ID: 31933306
The ketone (+/-)-5, which embodies the bicyclic core associated with the title tRNA synthetase inhibitors 1 and 2, has been…
Expand
Highly Cited
2000
Highly Cited
2000
Analogues of SB-203207 as inhibitors of tRNA synthetases.
M. Banwell
,
C. Crasto
,
+8 authors
W. Yue
Bioorganic & Medicinal Chemistry Letters
2000
Corpus ID: 33394231
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE